In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sobi gains exclusive US rights to AZ's Synagis; deal value tops $2.3bn

Executive Summary

AstraZeneca PLC sold Swedish Orphan Biovitrum AB (Sobi) exclusive rights to commercialize the respiratory syncytial virus therapy Synagis (palivizumab) in the US. Sobi will also participate in AZ’s share of profits and losses related to another RSV therapy MEDI8897 (being developed in Phase II trials under a deal between AZ and Sanofi Pasteur.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies